Safety, efficacy, immunogenicity study of GSK Biologicals’ HBV viral vector and adjuvanted proteins vaccine (GSK3528869A) in adult patients with chronic Hepatitis B infection

Trial Identifier: 204852
Sponsor: GlaxoSmithKline
Start Date: March 2019
Primary Completion Date: October 2024
Study Completion Date: October 2024
Condition: Hepatitis B

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Belgium Antwerpen, Belgium, 2650
Belgium Brussels, Belgium, 1000
Belgium Bruxelles, Belgium, 1070
Belgium Edegem, Belgium, 2650
Belgium Gent, Belgium, 9000
Belgium Leuven, Belgium, 3000
France Clichy Cedex, France, 92118
France CrEteil Cedex, France, 94010
France Lyon, France, 69317
France Strasbourg, France, 67091
Germany Aachen, Germany, 52074
Germany Berlin, Germany, 10787
Germany Bonn, Germany, 53127
Germany Essen, Germany, 45122
Germany Frankfurt, Germany, 60590
Germany Hamburg, Germany, 20246
Germany Mainz, Germany, 55131
Germany Tuebingen, Germany, 72076
Hong Kong Pokfulam, Hong Kong, NONE
Poland Krakow, Poland, 31-202
Poland Lancut, Poland, 37-100
Poland Myslowice, Poland, 41-400
Poland Poznan, Poland, 60-185
Spain Barcelona, Spain, 08011
Spain Barcelona, Spain, 08907
Spain COrdoba, Spain, 14004
Spain Granada, Spain, 18016
Spain Madrid, Spain, 28034
Spain Madrid, Spain, 28007
Spain Madrid, Spain, 28006
Spain MADRID, Spain, 28222
Spain Palma de Mallorca, Spain, 07120
Spain Santander, Spain, 39008
Spain Sevilla, Spain, 41013
Spain TorrejOn Ardoz Madrid, Spain, 28850
Taiwan Taichung, Taiwan, 40705
Taiwan Taichung, Taiwan, 40447
Taiwan Tainan, Taiwan, 704
Taiwan Taipei, Taiwan, 112
Taiwan Taoyuan, Taiwan, 333
Thailand Bangkok, Thailand, 10330
Thailand CHIANGMAI, Thailand, 50200
United Kingdom London, United Kingdom, SW17 0QT
United Kingdom London, United Kingdom, E1 1BB
United Kingdom Nottingham, United Kingdom, NG7 2UH